4-甲烷磺酰氧基哌啶 | 1347747-71-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-甲烷磺酰氧基哌啶
• 英文名称: 4-methanesulfonyloxypiperidine
• 英文别名: Piperidin-4-yl methanesulfonate
• CAS: 1347747-71-0
• 化学式: C₆H₁₃NO₃S
• mdl: MFCD22571401
• 分子量: 179.24
• InChiKey: IRWXYFWBGITFAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  63.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-甲烷磺酰氧基哌啶 、 potassium phtalimide 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-(Piperidin-4-yl)isoindoline
  参考文献：
  名称：

  [EN] DIPHENYLBUTYPIPERIDINE AUTOPHAGY INDUCERS
  [FR] INDUCTEURS, À BASE DE DIPHÉNYLBUTYLPIPÉRIDINE, DE L'AUTOPHAGIE

  摘要：

  公开号：

  WO2011143444A3

文献信息

• [EN] SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF<br/>[FR] COMPOSÉS DE PYRIMIDINE SUBSTITUÉE, COMPOSITIONS ET APPLICATIONS MÉDICINALES CORRESPONDANTES
  申请人：JUBILANT BIOSYS LTD

  公开号：WO2015025197A1

  公开（公告）日：2015-02-26

  The present disclosure relates to pyrimidine compounds of formula (I), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of preparation of these pyrimidine compounds, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders mediated by epidermal growth factor receptor (EGFR) family kinases.

  本公开涉及式(I)的嘧啶化合物，它们的立体异构体、互变异构体、药学上可接受的盐、多型体、溶剂合物和水合物。本公开还涉及制备这些嘧啶化合物的方法，以及含有它们的药物组合物。本公开的化合物在治疗、预防或抑制由表皮生长因子受体（EGFR）家族激酶介导的疾病和紊乱方面具有用途。
• [EN] QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS<br/>[FR] DERIVES DE QUINAZOLINE UTILISES COMME INHIBITEURS DE LA TYROSINE KINASE
  申请人：ASTRAZENECA AB

  公开号：WO2005026150A1

  公开（公告）日：2005-03-24

  The invention concerns quinazoline derivatives of the Formula (I); wherein each of R1, R2, W, X1, X2, Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula (I) are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.

  该发明涉及配方（I）的喹唑啉衍生物；其中R1、R2、W、X1、X2、Z、a和b在描述中有定义；它们的制备方法；含有它们的药物组合物以及它们在制造用于提供抗增殖效果的药物的用途。配方（I）的喹唑啉衍生物预计在治疗某些由erbB受体酪氨酸激酶介导的癌症等疾病中具有用处，特别是EGFR酪氨酸激酶。
• [EN] COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS SERVANT DE MODULATEURS DE L'ACTIVITÉ DE GPR119
  申请人：IRM LLC

  公开号：WO2009126535A1

  公开（公告）日：2009-10-15

  The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119; such as, but not limited to, diabetes, obesity and associated metabolic disorders. Formula (I) is a compound, in which A can have up to 2 ring -CH2- group substituted with -C(O)- and can be partially unsaturated with up to 2 double bonds; Wi and W2 are independently selected from CR10 and N; wherein R10 is selected from hydrogen and C1_6alkyl; Yi is selected from NRn, O and S; wherein Rn is selected from hydrogen and C1_ 6alkyl; Y2 and Y3 are independently selected from CH and N; Y4 is selected from CH2, OCH2 and NR15; wherein R15 is selected from hydrogen and C1_6alkyl; or the pharmaceutically acceptable salts thereof.

  本发明提供化合物、包含这些化合物的药物组合物以及使用这些化合物治疗或预防与GPR119活性相关的疾病或疾病，例如但不限于糖尿病、肥胖症和相关代谢障碍的方法。公式（I）是一种化合物，其中A可以有高达2个环-CH2-基团被-C（O）-取代，并且可以部分不饱和，具有高达2个双键；Wi和W2分别选自CR10和N；其中R10选自氢和C1_6烷基；Yi选自NRn、O和S；其中Rn选自氢和C1_6烷基；Y2和Y3分别选自CH和N；Y4选自 、O 和NR15；其中R15选自氢和C1_6烷基；或其药学上可接受的盐。
• [EN] 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM<br/>[FR] INHIBITEURS 5-AMINOPYRAZOLE-4-CARBOXAMIDE DE CDPK1 ISSUES DE T. GONDII ET C. PARVUM
  申请人：UNIV WASHINGTON CT COMMERCIALI

  公开号：WO2014189947A1

  公开（公告）日：2014-11-27

  The present disclosure is generally directed to compositions and methods for treating apicomplexan protozoan related disease, such as toxoplasmosis and cryptosporidiosis.

  本公开通常涉及用于治疗顶复门原虫相关疾病的组合物和方法，例如弓形虫病和隐孢子虫病。
• [EN] ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS<br/>[FR] DÉRIVÉS D'ARYL SULFONES COMME BLOQUEURS DES CANAUX CALCIQUES
  申请人：ZALICUS PHARMACEUTICALS LTD

  公开号：WO2011035159A1

  公开（公告）日：2011-03-24

  Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity, are disclosed. Specifically, a series of compounds containing aryl sulphone derivatives, as exemplified by Formula (I).

  揭示了在改善以不需要的钙通道活性为特征的情况下有效的方法和化合物，特别是不需要的N型和/或T型钙通道活性。具体来说，包含芳基磺酰基衍生物的一系列化合物被列举为示例，如公式（I）所示。